GLP-2 (Teduglutide) Phase 2 Trial for Environmental Enteric Dysfunction in Undernourished Women, Dhaka
ClinicalTrials.gov Studies
Summary
The NIH ClinicalTrials.gov registry published a Phase 2 clinical trial (NCT07537686) evaluating teduglutide (a GLP-2 analog) for treatment of environmental enteric dysfunction (EED) in 40 undernourished women aged 18-35 in Dhaka, Bangladesh. The randomized study will assess whether 30 days of daily subcutaneous teduglutide injections improve intestinal damage (via biopsy) and gut inflammation markers. icddr,b (Bangladesh) is a collaborating institution.
What changed
The NIH ClinicalTrials.gov registry added a Phase 2 interventional study (NCT07537686) testing teduglutide 0.05 mg daily subcutaneous injections over 30 days for environmental enteric dysfunction in undernourished women. Participants receive nutritional support and undergo upper GI endoscopy for EED confirmation at baseline and after treatment. The trial is conducted in urban slums of Dhaka, Bangladesh with icddr,b as a collaborating institution.
Affected parties including clinical investigators, pharmaceutical companies, and healthcare providers should note this trial advances the regulatory pathway for teduglutide in EED indications. The study targets a population with significant unmet medical need—undernourished women with histology-confirmed EED—and may inform future larger pivotal trials and potential regulatory submissions.
Archived snapshot
Apr 19, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Glucagon-like Peptide 2 (GLP-2) in Undernourished Women Improving From Histology-Confirmed Environmental Enteric Dysfunction (EED)
Phase 2 NCT07537686 Kind: PHASE2 Apr 17, 2026
Abstract
The goal of this clinical trial is to learn whether teduglutide, a medicine that helps the intestine heal, can improve environmental enteric dysfunction in undernourished women aged 18 to 35 years living in urban slums of Dhaka.
Environmental enteric dysfunction is a long-lasting condition of the small intestine. It causes inflammation and poor absorption of nutrients. Many people with this condition do not have clear symptoms, but it can make undernutrition worse. At present, there is no proven treatment for this condition.
The main questions this study aims to answer are:
- Does taking teduglutide for 30 days improve damage to the small intestine, as seen on intestinal biopsy?
- Does teduglutide improve blood and stool markers related to gut inflammation and nutrient absorption?
Participants will:
- Receive nutritional support at the start of the study
- Undergo an upper gastrointestinal endoscopy to confirm environmental enteric dysfunction
- Receive a daily injection of teduglutide under the skin for 30 days
- Undergo repeat endoscopy and laboratory tests after treatment to assess changes in gut health The results of this study will help researchers understand whether teduglutide may be a useful treatment for environmental enteric dysfunction in undernourished adult women and will guide future, larger studies.
Conditions: Environmental Enteric Dysfunction
Interventions: Teduglutide 0.05 dose
Related changes
Get daily alerts for ClinicalTrials.gov Studies
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from NIH.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ClinicalTrials.gov Studies publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.